Valneva Archives

News and Trends 5 Dec 2022

Positive antibody persistence for vaccine treating mosquito disease

A single shot vaccine for mosquito-borne disease chikungunya has had positive antibody persistence data 12 months after vaccination. The primary endpoint also met with a 99% seroresponse rate. The disease is caused by the chikungunya virus (CHIKV), a Togaviridae virus, transmitted by Aedes mosquitoes. Following positive immunogenicity and safety data from a phase 3 study […]

December 5, 2022 - 3 minutesmins - By Liza Laws

News and Trends 26 Oct 2021

Valneva’s Inactivated Covid-19 Vaccine Aces Phase III Trial

Last week, the French vaccine maker Valneva announced promising phase III trial results of its inactivated Covid-19 vaccine: a well-established technology that could confer broader immunity to the virus than shots currently on the market. Valneva’s vaccine candidate consists of a killed or ‘inactivated’ version of SARS-CoV-2, the virus responsible for Covid-19. The vaccine was […]

October 26, 2021 - 5 minutesmins - By Victor Kotsev

Chikungunya vaccine clinical trial Valneva

News and Trends 19 Aug 2021

Chikungunya Vaccine First to Succeed in Phase III Trial

In a significant step in the fight against tropical disease, the mosquito-borne viral disease chikungunya may become preventable with a new vaccine candidate from French biotech Valneva that just passed phase III trials. The results of the phase III trial revealed that a single dose of the live attenuated vaccine developed by Valneva induced the […]

August 19, 2021 - 3 minutesmins - By Victor Kotsev

dna sequencing covid 19 vaccine funding european biotech investment

News and Trends 10 Jun 2021

The Top European Biotech Investment Rounds in May

Last month saw huge biotech investment rounds dedicated to Covid-19 vaccines in Europe, including IPOs by Valneva and Vaccitech. However, a €227M (£195M) private round by the DNA sequencing giant Oxford Nanopore Technologies made the biggest splash. Last month was a difficult one for a number of public biotech companies. Biotech stock indices proved volatile […]

June 10, 2021 - 4 minutesmins - By Jonathan Smith

News and Trends 7 May 2020

Lyme Disease Vaccine Gets Pfizer’s Backing in €284M Deal

The French biotech Valneva will collaborate with Pfizer to develop and commercialize Valneva’s phase II-stage Lyme disease vaccine candidate. The deal they signed is expected to help compensate for the impact of the Covid-19 pandemic on Valneva’s financial outlook for 2020. The latest alliance will pool Valneva’s vaccine R&D expertise with Pfizer’s vast drug development […]

May 7, 2020 - 4 minutesmins - By Karen O’Hanlon Cohrt

News and Trends 18 Nov 2019

Update: Single-Shot Vaccine for Chikungunya Lasts for a Year in Phase I

Update (18/11/2019): French biotech Valneva has revealed additional phase I results concerning its experimental chikungunya vaccine; all 68 patients that were given a single injection of the vaccine showed sustained protection after 12 months. The company is currently running a phase II study and plans to launch a pivotal phase III trial next year. Update […]

November 18, 2019 - 3 minutesmins - By Jonathan Smith

Interview 4 Sep 2019

Overcoming Clinical Setbacks to Fight Insect-Borne Diseases

Sometimes things don’t go your way in the biotech industry. The CEO of Valneva, Thomas Lingelbach, shared his experience of migrating from big pharma to biotech, and how his first biotech company weathered phase III failures to develop vaccines for neglected diseases. Once confined to the less developed regions of the world, many insect-borne diseases […]

September 4, 2019 - 9 minutesmins - By Jonathan Smith

More News! 20 Nov 2018

Phase I Gives Hope for First Zika Vaccine

Results from a Phase I trial showed promising safety and efficacy of a potential first vaccine against the mosquito-borne Zika virus, developed by French biotech Valneva and US biopharma Emergent BioSolutions. In the US-based Phase I trial, 67 participants were injected with either placebo or inactivated forms of the virus as a vaccine. Two months later, […]

November 20, 2018 - 2 minutesmins - By Jonathan Smith

News and Trends 12 Dec 2016

French Biotech Puts a New Lyme Disease Vaccine on the Horizon

There is currently no vaccine for the fast-growing disease in the US, & treatments cost over $1Bn every year. Valneva might have a vaccine to stem the tide. Valneva, a commercial-stage biotech based in Lyon, France, has just received clearance from the FDA and its European counterpart to begin clinical trials for its experimental Lyme Disease […]

December 12, 2016 - 2 minutesmins - By Evelyn Warner

News and Trends 28 Aug 2015

[Update] Valneva’s duck stem cells attract two new Vaccine-deals

French Valneva continues to sign license agreements for its duck derived stem cell line that produces novel vaccines. Lyon-based Valneva was formed from the 70-year old duck breeder Group Grimaud. It entered the biotech scene in 2000 as Vivalis and today is on Euronext-Paris and the Vienna stock exchange, has a market cap of about €275M […]

August 28, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 18 Mar 2015

Valneva penetrates Chinese Market thanks to a license agreement

A few months ago, the article “An Anglo-French Partnership To Cure Hepatitis B” related Valneva partnerships with Immune Targeting Systems. Today Valneva, a leading pure play vaccines biotech company is again on the front of the stage by announcing the exclusive license agreement with the Chinese company Jianshun Biosciences to commercialize Valneva’s EB66 cell line […]

March 18, 2015 - 2 minutesmins - By Joachim Eeckhout

News and Trends 31 Jan 2015

An Anglo-French Partnership To Cure Hepatitis B

European biotechnology company Valneva and UK company Immune Targeting Systems (ITS) announced that they have signed an exclusive worldwide commercial license agreement. This deal grants ITS the rights to research, develop and commercialize Hepatitis B vaccine candidates in combination with Valneva’s IC31 Adjuvant. Valneva’s IC31 Adjuvant is a unique synthetic adjuvant combining the immuno-stimulating properties […]

January 31, 2015 - 2 minutesmins - By Lourdes Riquelme

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us